These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1694 related articles for article (PubMed ID: 32955176)

  • 61. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 62. KRAS G12C inhibition with sotorasib in metastatic colorectal cancer.
    Severi C; Van Cutsem E
    Ann Palliat Med; 2022 Aug; 11(8):2792-2795. PubMed ID: 35989651
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced
    Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC
    JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    Jiang Y; Zhang L
    J Thorac Oncol; 2024 Sep; 19(9):e43. PubMed ID: 39242149
    [No Abstract]   [Full Text] [Related]  

  • 66. A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    Ernst SM; von der Thüsen JH; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Sep; 19(9):e44-e45. PubMed ID: 39242150
    [No Abstract]   [Full Text] [Related]  

  • 67. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.
    Mahran R; Kapp JN; Valtonen S; Champagne A; Ning J; Gillette W; Stephen AG; Hao F; Plückthun A; Härmä H; Pantsar T; Kopra K
    ACS Chem Biol; 2024 Oct; 19(10):2152-2164. PubMed ID: 39283696
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sotorasib for Vascular Malformations Associated with
    Fraissenon A; Bayard C; Morin G; Benichi S; Hoguin C; Protic S; Zerbib L; Ladraa S; Firpion M; Blauwblomme T; Naggara O; Duruisseaux M; Delous M; Boitel C; Bringuier PP; Payen L; Legendre C; Kaltenbach S; Balducci E; Villarese P; Asnafi V; Bisdorff A; Guibaud L; Canaud G
    N Engl J Med; 2024 Jul; 391(4):334-342. PubMed ID: 39018528
    [No Abstract]   [Full Text] [Related]  

  • 71. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
    Brazel D; Nagasaka M
    Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sotorasib: a KRAS
    Ganguly A; Yoo E
    Trends Pharmacol Sci; 2022 Jun; 43(6):536-537. PubMed ID: 35461718
    [No Abstract]   [Full Text] [Related]  

  • 74. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
    Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
    J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
    Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
    J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
    [No Abstract]   [Full Text] [Related]  

  • 78. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
    Thomas QD; Quantin X; Lemercier P; Chouaid C; Schneider S; Filleron T; Remon-Masip J; Perol M; Debieuvre D; Audigier-Valette C; Justeau G; Loeb A; Hiret S; Clement-Duchene C; Dansin E; Stancu A; Pichon E; Bosquet L; Girard N; Du Rusquec P
    ESMO Open; 2024 Jun; 9(6):103473. PubMed ID: 38833966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 85.